Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F13%3A10209763" target="_blank" >RIV/00216208:11130/13:10209763 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/13:10209763
Result on the web
<a href="http://dx.doi.org/10.1007/s00345-012-0892-3" target="_blank" >http://dx.doi.org/10.1007/s00345-012-0892-3</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00345-012-0892-3" target="_blank" >10.1007/s00345-012-0892-3</a>

Result language
angličtina
Original language name
Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome
Original language description
Contemporary tools estimating increased risk of prostate cancer (PCa) relapse after radical prostatectomy (RP) are far from perfect and there has been an intensive search for additional predictive variables. We aimed to explore whether the parameters ofpostoperative ultrasensitive prostate-specific antigen (PSA) decline provide additional information for predicting PCa progression. A total of 319 consecutive men, with at least 2 years of follow-up after RP for clinically localized PCa were subjected tothis study. Intensive postoperative measurements of ultrasensitive PSA resulted in total of 4028 PSA values available for statistical evaluation. Biochemical recurrence (BCR) was defined as PSA a parts per thousand yen0.2 ng/ml. The accuracy of predictive models was quantified with the area under the curve. Over a median follow-up of 43 months (24-99 months), 107 patients (34 %) experienced BCR after RP. In patients with BCR, significantly higher values of PSA nadir (p < 0.001) and a de
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NT13472" target="_blank" >NT13472: Foundation of serum bank based on long-term monitored patients with prostate cancer, offering the possibility of verification of any association between newly identified oncomarkers and the disease progression.</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)